The timing of NICE’s review of the Aimovig verdict is unclear, and with Ajovy’s final guidance expected to be published next month Teva has an opportunity to access the NHS England market ...
The positive CHMP opinion is based on the review of a filing that included efficacy and safety data from the HALO clinical development programme. The programme evaluated Ajovy in two pivotal phase ...
Hosted on MSN12mon
Teva’s Ajovy yields positive data in post-hoc migraine analysisTeva Pharmaceuticals has announced positive results from post-hoc analysis of the Phase III HALO-LTS and FOCUS clinical trials that assessed Ajovy (fremanezumab) in patients with migraine and co ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback